These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 16533790

  • 1. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1623-9. PubMed ID: 16533790
    [Abstract] [Full Text] [Related]

  • 2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 3. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 4. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.
    J Pathol; 2009 Apr 15; 217(5):707-15. PubMed ID: 19156774
    [Abstract] [Full Text] [Related]

  • 5. Role of BRAF in thyroid oncogenesis.
    Caronia LM, Phay JE, Shah MH.
    Clin Cancer Res; 2011 Dec 15; 17(24):7511-7. PubMed ID: 21900390
    [Abstract] [Full Text] [Related]

  • 6. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 7. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL, Katoh R.
    Hum Pathol; 2007 Dec 01; 38(12):1810-8. PubMed ID: 17714762
    [Abstract] [Full Text] [Related]

  • 8. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK.
    J Endocrinol; 2011 Oct 01; 211(1):79-85. PubMed ID: 21795305
    [Abstract] [Full Text] [Related]

  • 9. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.
    Pathol Int; 2007 Jan 01; 57(1):12-20. PubMed ID: 17199737
    [Abstract] [Full Text] [Related]

  • 10. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.
    Cancer Res; 2009 Nov 01; 69(21):8317-25. PubMed ID: 19861538
    [Abstract] [Full Text] [Related]

  • 11. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.
    Mol Cancer Ther; 2007 Mar 01; 6(3):1070-8. PubMed ID: 17363500
    [Abstract] [Full Text] [Related]

  • 12. BAY 43-9006 inhibition of oncogenic RET mutants.
    Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M.
    J Natl Cancer Inst; 2006 Mar 01; 98(5):326-34. PubMed ID: 16507829
    [Abstract] [Full Text] [Related]

  • 13. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
    Liu D, Liu Z, Condouris S, Xing M.
    J Clin Endocrinol Metab; 2007 Jun 01; 92(6):2264-71. PubMed ID: 17374713
    [Abstract] [Full Text] [Related]

  • 14. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
    Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C.
    Mol Cancer Res; 2008 May 01; 6(5):751-9. PubMed ID: 18458053
    [Abstract] [Full Text] [Related]

  • 15. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 01; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 16. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R.
    J Pathol; 2008 Feb 01; 214(3):320-7. PubMed ID: 18098337
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M, Müller S, Britten M, Worm K, Schmid KW, Mann K, Fuhrer D.
    BMC Cancer; 2015 Mar 26; 15():184. PubMed ID: 25879531
    [Abstract] [Full Text] [Related]

  • 18. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W, Li XH, Zhang YH, Li J, Chen J, Zhao P, Li QY, Xiang JJ, Li X, Xu RJ.
    Zhonghua Zhong Liu Za Zhi; 2011 May 26; 33(5):354-7. PubMed ID: 21875464
    [Abstract] [Full Text] [Related]

  • 19. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 26; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 20. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G.
    J Clin Endocrinol Metab; 2010 Jan 26; 95(1):450-5. PubMed ID: 19880792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.